The FDA cleared Edesa Biotech's Investigational New Drug application for its Phase 2 clinical study of EB06 in vitiligo, allowing the company to expand patient recruitment to the United States. The double-blind, placebo-controlled trial evaluates EB06, a monoclonal antibody targeting CXCL10, in up to 80 adults with moderate-to-severe nonsegmental vitiligo. Participants are randomized 1:1 to receive either EB06 or placebo every two weeks through Week 22, with the primary efficacy endpoint being the mean percent change from baseline in the Facial Vitiligo Area Scoring Index at Week 28. Topline data is anticipated by the fourth quarter of 2027. Edesa Biotech operates as a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases.
